ArticleEmerging microbes & infections2026
A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuous antigenic drift of zoonotic H7 avian influenza viruses remains a significant global public health threat. While monoclonal antibodies (mAbs) targeting the hemagglutinin (HA) head offer potent neutralization, their efficacy is often undermined by rapid viral escape. In this study, we systematically mapped the antigenic architecture of the H7 HA head domain using a panel of 30 murine mAbs. By integrating epitope mapping with longitudinal evolutionary analysis of over 2,500 isolates, we identified highly conserved, functionally constrained residues, specifically G70, G132, N167, and M173, that remained nearly invariant over decades. Leveraging these insights, we engineered a chimeric bispecific antibody (BsAb-H7) to simultaneously engage two distinct, non-overlapping conserved epitopes. BsAb-H7 demonstrated broad neutralization breadth across divergent H7N9, H7N7, and H7N3 subtypes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.